Hidaka, Hisashi http://orcid.org/0000-0002-4151-5663
Izumi, Namiki
Aramaki, Takeshi
Ikeda, Masafumi
Inaba, Yoshitaka
Imanaka, Kazuho
Okusaka, Takuji
Kanazawa, Susumu
Kaneko, Shuichi
Kora, Shinichi
Saito, Hiroya
Furuse, Junji
Matsui, Osamu
Yamashita, Tatsuya
Yokosuka, Osamu
Morita, Satoshi
Arioka, Hitoshi
Kudo, Masatoshi
Arai, Yasuaki
Funding for this research was provided by:
Taiho Pharmaceutical
Article History
Received: 19 February 2019
Accepted: 17 April 2019
First Online: 3 May 2019
Compliance with ethical standards
:
: Hidaka H has received personal fees from Taiho Pharmaceutical. Izumi N has received personal fees from Gilead, AbbVie, Otsuka and Shionogi. Aramaki T has received personal fees from Taiho. Ikeda M has received: personal fees from Taiho, Bayer, Eisai,Bristol-Myers Squibb, Eli Lilly Japan, Daiichi-Sankyo, Kyowa Hakko Kirin, Novartis Pharma, Yakult, Abbott Japan, Chugai Pharmaceutical, Nippon Kayaku, Otsuka, Pharmaceutical and Bristol-Myers Squibb. Ikeda M has received other from Taiho Pharmaceutical, Bayer Yakuhin, Eisai, Bristol-Myers Squibb, Eli Lilly Japan, Daiichi-Sankyo, Kyowa Hakko Kirin, TEIJIN PHARMA, Novartis Pharma, Shire, Chugai Pharmaceutical, Ono Pharmaceutical, AstraZeneca, Zeria Pharmaceutical, Baxter, Kowa, Boehringer Ingelheim, Glaxo Smithkline, Nano Carrier, ASLAN Pharmaceuticals. Inaba Y has received personal fees from Eisai, Medicon, Bayer Yakuhin, Guerbet Japan, Nippon Kayaku, Canon Medical Systems, Toray Medical. Okusaka T has received other from Merck Serono, Suimtomo Dainippon, Yakult, Ono, Novartis, Eli Lilly Japan, Chugai, AstraZeneca, Eisai and Baxter. Kaneko S has received other from Taiho. Furuse J has received: grant from Taiho, Yakult, Eli Lilly Japan, Chugai, Eisai, Ono, Kyowa Hakko Kirin, Sumitomo Dainippon, Astellas, MSD, J-Pharma, Daiichi Sankyo, Janssen, Zeria, Merck Serono, Onco Therapy Science, Bayer, Takeda, Shire, Pfizer, Bristol-Myers Squibb, Novartis, Astra Zeneca, Mochida and Shionogi; personal fees from Taiho, Yakult, Eli Lilly japan, Chugai, Eisai, Ono, Kyowa Hakko Kirin, Sumitomo Dainippon, Astellas, J-Pharma, Daiichi Sankyo, Zeria, Merck Serono, Bayer, Takeda, Shire, Pfizer, Bristol-Myers Squibb, Novartis, Astra Zeneca, Mochida, Shionogi, EA Pharma, Mitsubishi Tanabe, Sawai, Sanofy, Sandoz, Boehringer Ingelheim, Otsuka and Fujifilm. Yamashita T has received personal fees from Taiho Pharmaceutical. Yokosuka O has received other from Tanabe-Mitsubishi, Otsuka, Eisai, Daiichi Sankyo, MSD, Gilead, Chugai, Astellas, Takeda and Sumitomo Dainippon. Morita S has received personal fees from Taiho. Arioka H has received personal fees from Taiho and Chugai. Kudo M has received: grant from Taiho, Chugai, Otsuka, Takeda, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, Abbvie, Medico’s Hirata, Astellas Pharma and Bristol-Myers Squibb; personal fees from Taiho, MSD, Eisai, Bayer and Ajinomoto. Arai Y has received personal fees from Taiho. All remaining authors have declared no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.